DDrare: Database of Drug Development for Rare Diseases

38. スティーヴンス・ジョンソン症候群
［臨床試験数：11，薬物数：19（DrugBank：8），標的遺伝子数：14，標的パスウェイ数：98］

Searched query = "Stevens-Johnson syndrome", "SJS", "Mucocutaneous ocular syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 0.05%cyclosporin eye drop; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine; Cultivated oral mucosal epithelial sheet transplantation; Cyclosporin; Cyclosporine; Cyclosporine 5 mg/kg bid days 0-14; Etanercept; Etanercept 50 mg sc day 0 and day 3; Harmonized supportive care; Infliximab; Intravenous immunoglobulin; Lamotrigine; Lamotrigine - generic product; Methylprednisolone; Palifermin; Prednisolone; Riboflavin; Site specific standard of care comparison; Topical infliximab

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02987257 (ClinicalTrials.gov)	April 2021	25/11/2016	NATIENS: Optimal Management and Mechanisms of SJS/TEN	NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis	Stevens-Johnson Syndrome;Toxic Epidermal Necrolyses	Drug: Harmonized supportive care;Drug: Cyclosporine 5 mg/kg bid days 0-14;Drug: Etanercept 50 mg sc day 0 and day 3	Vanderbilt University Medical Center	University of Ottawa;University of Toronto	Not yet recruiting	18 Years	N/A	All	267	Phase 3	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02987257
(ClinicalTrials.gov)

April 2021

25/11/2016

NATIENS: Optimal Management and Mechanisms of SJS/TEN

NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Stevens-Johnson Syndrome;Toxic Epidermal Necrolyses

Drug: Harmonized supportive care;Drug: Cyclosporine 5 mg/kg bid days 0-14;Drug: Etanercept 50 mg sc day 0 and day 3

Vanderbilt University Medical Center

University of Ottawa;University of Toronto

Not yet recruiting

18 Years

N/A

All

267

Phase 3

United States